^
    Back
    Association details:
    Biomarker:OPCML underexpression + AXL overexpression
    Cancer:Hepatocellular Cancer
    Drug:bemcentinib (BGB324) (AXL inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    In Vivo
    Title:

    Combined OPCML and AXL Expression as a Prognostic Marker and OPCML Enhances AXL Inhibitor in Cholangiocarcinoma

    Excerpt:
    ...we also addressed whether OPCML enhanced the sensitivity of CCA cells to AXL inhibitor R428 in vitro….patients with combined low OPCML/high AXL expression had significantly shorter overall survival (p=0.007). OPCML enhanced the effect of AXL inhibitor R428 in AXL-expressing CCA cell lines.
    DOI:
    10.21873/invivo.12816